Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Research & Development (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Research & Development for 10 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 68.63% year-over-year to $2.6 million, compared with a TTM value of $12.7 million through Dec 2025, down 69.73%, and an annual FY2025 reading of $12.7 million, down 69.73% over the prior year.
  • Research & Development was $2.6 million for Q4 2025 at Zevra Therapeutics, down from $3.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.3 million in Q3 2023 and bottomed at $2.2 million in Q3 2021.
  • Average Research & Development over 5 years is $6.2 million, with a median of $5.1 million recorded in 2022.
  • The sharpest move saw Research & Development soared 180.82% in 2023, then crashed 73.46% in 2025.
  • Year by year, Research & Development stood at $2.8 million in 2021, then skyrocketed by 126.13% to $6.4 million in 2022, then skyrocketed by 79.8% to $11.4 million in 2023, then dropped by 26.87% to $8.4 million in 2024, then tumbled by 68.63% to $2.6 million in 2025.
  • Business Quant data shows Research & Development for ZVRA at $2.6 million in Q4 2025, $3.4 million in Q3 2025, and $3.4 million in Q2 2025.